24Zika virus (ZIKV) specific neutralizing antibodies hold a great promise for 25 antibody-based interventions and vaccine design against ZIKV infection. 26 However, their development in infected patients remain unknown. Here, we 27 report on the dynamic development of a potent and protective ZIKV-specific 28 human antibody ZK2B10 initially isolated from a ZIKV convalescent individual 29 using next-generation sequencing (NGS). The unbiased repertoire analysis 30 showed dramatic changes in many families of heavy and light chain variable 31 regions. However, lineage tracing of ZK2B10 revealed limited somatic 32 hypermutation throughout the 12 months since the onset of symptom. In 33 particular, NGS-derived germline-like somatic variants neutralized and 34 protected mice from lethal challenge of ZIKV without detectable cross-reactivity 35 with Dengue virus (DENV). Site-directed mutagenesis identified two residues 36 within chain, N31 and S91 that are essential to the functional maturation. The 37 dynamic features unveiled here will assist us to better understand the 38 pathogenesis of ZIKV infection and inform rational design of vaccines.
39Author summary 40 Recently emerged ZIKV is associated with severe neurological complications 41 such as Guillain-Barré syndrome in adults and congenital microcephaly in 42 newborns. No ZIKV-specific therapeutics or vaccines are currently available. 43 We and others have identified a number of neutralizing antibodies capable of 44 protecting experimental animals from ZIKV infection. However, the 3 45 development of these potent antibodies during ZIKV natural infection remains 46 unknown. Here, we report on the longitudinal analysis of one such antibody 47 ZK2B10 using next-generation sequencing (NGS), bioinformatics and 48 functional analysis. We found that the ZK2B10 germline-like antibodies 49 possess strong neutralizing activity in vitro and impressive protectivity against 50 lethal ZIKV infection in vivo. These findings suggest that the potent and 51 protective antibody response against ZIKV can be generated within relative 52 short term with high germline identity which provide great hope and promise for 53 successful vaccine development against ZIKV. 54 Key words 55 Zika virus infection, Guillain-Barré syndrome, microcephaly, neutralizing 56 antibody, antibody repertoire, next-generation sequencing 57 Introduction 58 Zika virus (ZIKV), a member of the Flavivirus genus of the Flaviviridae family, 59 is an emerging mosquito-borne pathogen. ZIKV is closely related to other 60 flavivirus such as dengue (DENV 1, 2, 3 and 4), yellow fever (YFV), West Nile 61 (WNV), Japanese encephalitis (JEV), and tick-borne encephalitis (TBEV) 62 viruses [1]. Since ZIKV was first identified in 1947 among rhesus macaques of 63 Uganda Zika forest, its new variants have become increasingly prevalent and 64 adapted to the human population as recent outbreaks have spread across the 65 Americas, Caribbean, and Southeast Asia [2-5]. At the peak of the 2016 4 66 outbreak, several incidents o...